A novel infusible botanically-derived drug, PG2, for cancer-related fatigue: A phase II double-blind, randomized placebo-controlled study

Hong Wen Chen, I. Hsin Lin, Yu Jen Chen, Kao Hwa Chang, Meng Hao Wu, Wen Hao Su, Gwo Che Huang, Yuen Liang Lai

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: This study investigated the efficacy of the botanical-derived drug, PG2, a partially purified extract of Astragalus membranaceus, as a complementary and palliative medicine for managing cancer-related fatigue (CRF). Methods: Patients with advanced cancer and moderate to severe CRF were randomized to receive either PG2 or a placebo (normal saline, NS) in the first treatment cycle (four weeks) in a double-blind manner; thereafter, on the next cycle (four weeks), all patients received open-label treatment with PG2. Results: PG2 significantly improved CRF in the NS-primed group. In the first four week cycle, PG2 administration resulted in a greater fatigue-improvement response rate than seen with NS alone. In addition, approximately 82% of patients who reported an improvement of fatigue symptoms following the first cycle of PG2 experienced sustained benefits after administration of the second treatment cycle. Among patients treated with PG2 who did not report an improvement in symptoms throughout the first treatment cycle, approximately 71% showed significant improvement after the second treatment cycle. No major or irreversible toxicities were observed with PG2 treatment. Conclusion: PG2 might be an effective and safe treatment for relieving CRF among advanced cancer patients.

Original languageEnglish
JournalClinical and Investigative Medicine
Volume35
Issue number1
Publication statusPublished - 2012

Fingerprint

Fatigue
Placebos
Pharmaceutical Preparations
Neoplasms
Therapeutics
Astragalus membranaceus
Second Primary Neoplasms
Complementary Therapies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A novel infusible botanically-derived drug, PG2, for cancer-related fatigue : A phase II double-blind, randomized placebo-controlled study. / Chen, Hong Wen; Lin, I. Hsin; Chen, Yu Jen; Chang, Kao Hwa; Wu, Meng Hao; Su, Wen Hao; Huang, Gwo Che; Lai, Yuen Liang.

In: Clinical and Investigative Medicine, Vol. 35, No. 1, 2012.

Research output: Contribution to journalArticle

Chen, Hong Wen ; Lin, I. Hsin ; Chen, Yu Jen ; Chang, Kao Hwa ; Wu, Meng Hao ; Su, Wen Hao ; Huang, Gwo Che ; Lai, Yuen Liang. / A novel infusible botanically-derived drug, PG2, for cancer-related fatigue : A phase II double-blind, randomized placebo-controlled study. In: Clinical and Investigative Medicine. 2012 ; Vol. 35, No. 1.
@article{8771e89c6d9c44d79b0e1379c8d7740d,
title = "A novel infusible botanically-derived drug, PG2, for cancer-related fatigue: A phase II double-blind, randomized placebo-controlled study",
abstract = "Purpose: This study investigated the efficacy of the botanical-derived drug, PG2, a partially purified extract of Astragalus membranaceus, as a complementary and palliative medicine for managing cancer-related fatigue (CRF). Methods: Patients with advanced cancer and moderate to severe CRF were randomized to receive either PG2 or a placebo (normal saline, NS) in the first treatment cycle (four weeks) in a double-blind manner; thereafter, on the next cycle (four weeks), all patients received open-label treatment with PG2. Results: PG2 significantly improved CRF in the NS-primed group. In the first four week cycle, PG2 administration resulted in a greater fatigue-improvement response rate than seen with NS alone. In addition, approximately 82{\%} of patients who reported an improvement of fatigue symptoms following the first cycle of PG2 experienced sustained benefits after administration of the second treatment cycle. Among patients treated with PG2 who did not report an improvement in symptoms throughout the first treatment cycle, approximately 71{\%} showed significant improvement after the second treatment cycle. No major or irreversible toxicities were observed with PG2 treatment. Conclusion: PG2 might be an effective and safe treatment for relieving CRF among advanced cancer patients.",
author = "Chen, {Hong Wen} and Lin, {I. Hsin} and Chen, {Yu Jen} and Chang, {Kao Hwa} and Wu, {Meng Hao} and Su, {Wen Hao} and Huang, {Gwo Che} and Lai, {Yuen Liang}",
year = "2012",
language = "English",
volume = "35",
journal = "Clinical and Investigative Medicine",
issn = "0147-958X",
publisher = "The Canadian Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - A novel infusible botanically-derived drug, PG2, for cancer-related fatigue

T2 - A phase II double-blind, randomized placebo-controlled study

AU - Chen, Hong Wen

AU - Lin, I. Hsin

AU - Chen, Yu Jen

AU - Chang, Kao Hwa

AU - Wu, Meng Hao

AU - Su, Wen Hao

AU - Huang, Gwo Che

AU - Lai, Yuen Liang

PY - 2012

Y1 - 2012

N2 - Purpose: This study investigated the efficacy of the botanical-derived drug, PG2, a partially purified extract of Astragalus membranaceus, as a complementary and palliative medicine for managing cancer-related fatigue (CRF). Methods: Patients with advanced cancer and moderate to severe CRF were randomized to receive either PG2 or a placebo (normal saline, NS) in the first treatment cycle (four weeks) in a double-blind manner; thereafter, on the next cycle (four weeks), all patients received open-label treatment with PG2. Results: PG2 significantly improved CRF in the NS-primed group. In the first four week cycle, PG2 administration resulted in a greater fatigue-improvement response rate than seen with NS alone. In addition, approximately 82% of patients who reported an improvement of fatigue symptoms following the first cycle of PG2 experienced sustained benefits after administration of the second treatment cycle. Among patients treated with PG2 who did not report an improvement in symptoms throughout the first treatment cycle, approximately 71% showed significant improvement after the second treatment cycle. No major or irreversible toxicities were observed with PG2 treatment. Conclusion: PG2 might be an effective and safe treatment for relieving CRF among advanced cancer patients.

AB - Purpose: This study investigated the efficacy of the botanical-derived drug, PG2, a partially purified extract of Astragalus membranaceus, as a complementary and palliative medicine for managing cancer-related fatigue (CRF). Methods: Patients with advanced cancer and moderate to severe CRF were randomized to receive either PG2 or a placebo (normal saline, NS) in the first treatment cycle (four weeks) in a double-blind manner; thereafter, on the next cycle (four weeks), all patients received open-label treatment with PG2. Results: PG2 significantly improved CRF in the NS-primed group. In the first four week cycle, PG2 administration resulted in a greater fatigue-improvement response rate than seen with NS alone. In addition, approximately 82% of patients who reported an improvement of fatigue symptoms following the first cycle of PG2 experienced sustained benefits after administration of the second treatment cycle. Among patients treated with PG2 who did not report an improvement in symptoms throughout the first treatment cycle, approximately 71% showed significant improvement after the second treatment cycle. No major or irreversible toxicities were observed with PG2 treatment. Conclusion: PG2 might be an effective and safe treatment for relieving CRF among advanced cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84861316948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861316948&partnerID=8YFLogxK

M3 - Article

C2 - 22309959

AN - SCOPUS:84861316948

VL - 35

JO - Clinical and Investigative Medicine

JF - Clinical and Investigative Medicine

SN - 0147-958X

IS - 1

ER -